Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
March 13th, 2018
15.1K views
We describe a protocol for preclinical in vivo tracking of cancer metastasis. It is based on a radionuclide-fluorescence reporter combining the sodium iodide symporter, detected by non-invasive [18F]tetrafluoroborate-PET, and a fluorescent protein for streamlined ex vivo confirmation. The method is applicable for preclinical in vivo cell tracking beyond tumor biology.
Overview
This protocol outlines a method for tracking tumor growth and metastasis in live rodents using a radionuclide-fluorescence reporter. The technique employs non-invasive imaging via positron emission tomography (PET) combined with ex vivo confirmation through fluorescence.
Key Study Components
Area of Science
- Oncology
- Imaging Techniques
- Preclinical Research
Background
- Tracking cancer metastasis is crucial for understanding tumor biology.
- Existing methods often require extensive animal use and can be invasive.
- This study introduces a more efficient and less invasive imaging technique.
- The automated synthesis of the PET tracer simplifies the process significantly.
Purpose of Study
- To develop a method for real-time tracking of cancer cells in vivo.
- To enhance understanding of metastasis and treatment effects on tumor progression.
- To reduce the number of animals needed for preclinical testing.
Methods Used
- Generation of lentivirus particles and transduction of cells.
- Use of F18 tetrafluoroborate for PET imaging.
- In vivo imaging of tumor-bearing mice after radiotracer injection.
- Analysis of tissue radioactivity and histological examination.
Main Results
- Successful tracking of tumor progression and metastasis in rodent models.
- Demonstrated specificity of the radionuclide-fluorescence reporter.
- Provided insights into the dynamics of cancer cell behavior.
- Showed potential for tracking therapeutic effects alongside tumor growth.
Conclusions
- The method offers a significant advancement in cancer research methodologies.
- It allows for detailed monitoring of tumor dynamics over time.
- This technique can facilitate the development of new cancer therapies.
Frequently Asked Questions
What is the main advantage of this imaging technique?
The technique is non-invasive and reduces the number of animals needed for research.
How does the radionuclide-fluorescence reporter work?
It combines PET imaging with fluorescence for accurate tracking of cancer cells.
What are the implications of this study?
It can enhance understanding of cancer biology and improve therapeutic testing.
Is the method suitable for other types of cells?
Yes, it can be adapted for tracking various cell types in vivo.
What are the key steps in the protocol?
Key steps include cell transduction, radiotracer preparation, and imaging.
How can this method contribute to cancer treatment research?
It allows for real-time monitoring of treatment effects on tumor progression.
Executive Industry Relevance
This method enables longitudinal, non-invasive tracking of tumor progression and metastasis in live rodent models, addressing a critical gap in preclinical oncology research. By combining PET imaging with fluorescence confirmation, it provides quantitative, repeatable data that reduces animal use and improves statistical power. The approach supports mechanistic de-risking of therapeutic candidates by visualizing spontaneous metastasis and treatment effects over time.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by visualizing tumor growth and metastatic spread in vivo.
- Operational Value: Supports functional target validation through specific NIS-mediated radiotracer uptake, confirmed by ex vivo fluorescence.
- Predictive Value: Enhances confidence in target engagement and pathway modulation by providing longitudinal, quantifiable imaging data.
Screening & Assay Development
- Scientific Value: Generates standardized, quantitative PET readouts (SUV) that enable reliable comparison across experimental conditions.
- Operational Value: Facilitates assay readiness through automated radiotracer production and repeat imaging sessions, improving throughput.
- Scalability: Reduces required cohort sizes via longitudinal design, supporting efficient resource allocation in screening campaigns.
Translational & Preclinical Research
- Translational Continuity: Bridges discovery and preclinical stages by enabling continuous monitoring of tumor dynamics from early growth to metastasis.
- Biomarker Alignment: Supports evaluation of therapeutic impact on lesion burden and distribution, informing go/no-go decisions.
- Risk-Adjusted Advancement: Provides longitudinal imaging data that improves predictability of therapeutic efficacy in complex metastasis models.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through lead identification to preclinical efficacy testing, enabling non-invasive monitoring at each stage.
- Discovery Biology: Supports hypothesis testing and pathway clarification by tracking cellular localization, expansion, and metastasis over time.
- Screening: Delivers reproducible, quantitative imaging outputs (SUV, lesion volume) that allow comparison of compound effects across time points.
- Analytics: Generates standardized uptake values and volumetric metrics that facilitate cross-functional data interpretation and statistical modeling.
- Translational Research: Connects in vivo imaging findings to ex vivo histology and cytometry, ensuring mechanistic consistency across validation stages.
- Enterprise Reuse: Establishes a reusable imaging platform applicable to diverse cell lines and disease models beyond oncology, such as stem cell or immune cell tracking.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence by reducing mechanistic ambiguity in metastasis models through direct, longitudinal visualization.
- Operational Value: Enhances reproducibility and standardization via automated tracer production and standardized imaging protocols.
- Strategic Value: Improves capital efficiency by decreasing animal numbers and enabling data-rich longitudinal studies.
- Portfolio Impact: Informs risk-adjusted prioritization by providing early, quantitative insights into therapeutic effects on tumor progression and metastatic spread.
Implementation Considerations
- Requires expertise in molecular cloning, lentiviral transduction, and reporter gene characterization.
- Depends on access to automated radiosynthesis platforms, PET/CT scanners, and radiation safety infrastructure.
- Necessitates cross-team standardization between molecular biology, imaging, and histology workflows for consistent data interpretation.
- Involves adaptation considerations when applying the NIS-FP reporter to different cell types or species, including validation of tracer uptake and fluorescence signal.
- Involves practical limitations related to radiation handling, isotope decay (F-18 half-life), and the need for timely synthesis and imaging scheduling.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in longitudinal imaging studies?
Null hypothesis testing ensures observed changes in tumor progression or metastasis are statistically significant and not due to random variation, supporting confident target engagement conclusions.
How does independent variable isolation fit the discovery pipeline in reporter gene imaging?
Isolating variables such as gene expression or treatment exposure allows clear attribution of imaging changes to specific biological interventions, improving target validation rigor.
What quantitative dependent variable measurements enable reliable tracking of tumor progression?
Standardized uptake values (SUV) and lesion volume measurements provide quantifiable, repeatable metrics for assessing tumor burden and metastatic spread over time.
Why do replication requirements matter for cross-functional collaboration in imaging-based studies?
Replication across animals and time points ensures data consistency, enabling reliable comparison between discovery, preclinical, and translational teams using shared imaging endpoints.
What statistical analysis capabilities are required before implementing longitudinal PET imaging in drug discovery?
Capabilities for analyzing repeated measures, longitudinal trends, and inter-group differences are essential to extract meaningful insights from serial imaging data and support go/no-go decisions.
Chapters in this video
0:04
Title
1:40
Engineering and Characterization of Cancer Cells to Express the Radionuclide-fluorescence Fusion Reporter NIS-FP and [18F]BF4 - Synthesis
4:04
In Vivo Imaging of NIS-FP Expressing Cells by nanoPET/CT
5:40
Ex Vivo Analyses
6:33
Results: Radiotracer Uptake in Cell Lines is Due to Specific NIS-FP Expression
8:24
Conclusion
